Capricor Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesChemicals & Related Products · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
10865 Road to the Cure Ste 150, San Dieg...Phone Number
(858) 727-1755Website
www.capricor.comRevenue
$11.1 MillionStock Symbol
CAPRIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
3
1
1
1
1
About Capricor Therapeutics
Capricor Therapeutics is a biotechnology company with a mission to develop groundbreaking therapies that make a meaningful impact on patients lives. Capricor is focused on the development of biologics, primarily cell and exosome-based technologies to treat or prevent a broad range of diseases.Explore more
Capricor Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Capricor Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Capricor Therapeutics is spiking on competitors!
Check if Capricor Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Capricor Therapeutics has new funding data
Earning: See what the market has to say on Capricor Therapeutics recently announced quarterly report
Product Launch: Get notified when Capricor Therapeutics launches new products
Click to see if Capricor Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Capricor Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Capricor Therapeutics
Recommended Actions
Find VP level buyers at Capricor Therapeutics
Find more new buyers
Compare Similar Companies to Capricor Therapeutics
Compare insights from companies similar to Capricor Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Capricor Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Capricor Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Capricor Therapeutics.
Capricor Therapeutics financials insights
Gather financial insights about Capricor Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$150K
2024
Private Equity
$35M
Capricor Therapeutics Tech Stack
A closer look at the technologies used by Capricor Therapeutics
Most Recent Scoops
Hiring Plans
Capricor Therapeutics has more open roles in Operations than it has had at any time in the past 12 months. Technologies mentioned include: KnowBe4, Crowdstrike, Directly, Remote, Rapid 7, and Abnormal Security. Areas of expertise include: Good Manufacturing Practices, Escalation Procedures, Cross-Functional Collaboration, Supplier Development, Supplier Performance Analysis, Supplier Audit, and Corporate Services.
Hiring Plans
Pain Point
Capricor Therapeutics has disclosed that its distribution agreement with NS Pharma is currently non-transactable, that it does not expect NS Pharma to make future milestone payments, and that in the event of rescission, Capricor Therapeutics is prepared to repay the approximately $50 million received in upfront and milestone payments from NS Pharma.
Contracts
Project
Capricor Therapeutics has announced that the HOPE-3 pivotal Phase III trial for Deramiocel met its primary efficacy endpoint the Performance of the Upper Limb (PUL) version 2.0 demonstrating an approximately 54% reduction in disease severity at 12 months (p=0.029), with all Type I error-controlled secondary endpoints also achieving statistical significance. The multicenter, randomized, double-blind, placebo-controlled study enrolled 106 patients in a 1-to-1 randomization scheme.
Medical Research, Clinical Operations
Pain Point
Capricor Therapeutics is facing a structural pricing flaw in its commercialization and distribution agreement with NS Pharma that would make it economically impossible to deliver Deramiocel to patients covered by Medicare, Medicaid, or private insurance, with providers potentially facing hundreds of thousands of dollars in reimbursement shortfalls per dose.
Pain Point, Pharmaceuticals
Pain Point
Lawsuits, Legal Affairs, Contracts
Capricor Therapeutics News & Media
Capricor Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that senior management will participate in the following upcoming investor conferences.Deramiocel Outlook Strengthens Capricor Therapeutics, Inc. (CAPR) as a Small-Cap Stock to Buy
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is one of the most shorted mid-cap and small-cap stocks to buy now. On May 13, B Riley reiterated a Buy rating on Capricor Therapeutics (NASDAQ:CAPR) with a $63 price target. The positive stance comes as the company enters into a pivotal stage in the potential approval of Deramiocel for the […]Capricor Therapeutics Expands Commercial Leadership Team
--Michael Maurer joins as Chief Commercial Officer, further strengthening Capricor’s launch readiness efforts for Deramiocel in Duchenne…...Capricor Therapeutics Q1 Earnings Call Highlights
Capricor Therapeutics (NASDAQ:CAPR) said its Duchenne muscular dystrophy therapy candidate deramiocel remains under active FDA review, while the company is preparing to commercialize the product itself amid a legal dispute with distribution partner NS Pharma and parent company Nippon Shinyaku. On t
Read more news
Top Chemicals & Related Products Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Capricor Therapeutics
Sign Up For FreeTo access detailed company insights
Capricor Therapeutics is a biotechnology company with a mission to develop groundbreaking therapies that make a meaningful impact on patients lives. Capricor is focused on the development of biologics, primarily cell and exosome-based technologies to treat or prevent a broad range of diseases.... Read More
